Journal Guides5 min readUpdated Apr 6, 2026

Circulation Impact Factor

Circulation impact factor is 38.6. See the current rank, quartile, and what the number actually means before you submit.

Associate Professor, Clinical Medicine & Public Health

Author context

Specializes in clinical and epidemiological research publishing, with direct experience preparing manuscripts for NEJM, JAMA, BMJ, and The Lancet.

Journal evaluation

Want the full picture on Circulation?

See scope, selectivity, submission context, and what editors actually want before you decide whether Circulation is realistic.

Open Circulation GuideAnthropic Privacy Partner. Zero-retention manuscript processing.Run Free Readiness Scan
Metric context

A fuller snapshot for authors

Use Circulation's impact factor as one signal, then stack it against selectivity, editorial speed, and the journal guide before you decide where to submit.

Open full journal guide
Impact factor38.6Current JIF
CiteScore40.5Scopus 4-year window
Acceptance rate~7%Overall selectivity
First decision17 daysProcess speed

What this metric helps you decide

  • Whether Circulation has the citation profile you want for this paper.
  • How the journal compares to nearby options when prestige or visibility matters.
  • Whether the citation upside is worth the likely selectivity and process tradeoffs.

What you still need besides JIF

  • Scope fit and article-type fit, which matter more than a high number.
  • Desk-rejection risk, which impact factor does not predict.
  • Timeline and cost context.

CiteScore: 40.5. These longer-window metrics help show whether the journal's citation performance is stable beyond a single JIF snapshot.

Submission context

How authors actually use Circulation's impact factor

Use the number to place the journal in the right tier, then check the harder filters: scope fit, selectivity, and editorial speed.

Use this page to answer

  • Is Circulation actually above your next-best alternatives, or just more famous?
  • Does the prestige upside justify the likely cost, delay, and selectivity?
  • Should this journal stay on the shortlist before you invest in submission prep?

Check next

  • Acceptance rate: ~7%. High JIF does not tell you how hard triage will be.
  • First decision: 17 days. Timeline matters if you are under a grant, job, or revision clock.
  • Publishing cost and article type, since those constraints can override prestige.

Quick answer

Circulation has a 2024 JCR impact factor of 38.6 and sits at the top of its JCR cardiology category, but the real decision logic is narrower than that. This is the flagship AHA journal for papers that change how a broad cardiovascular audience interprets practice, prognosis, or disease biology. If the work is strong but mostly subspecialty-facing, the metric alone is not the right reason to submit here.

Circulation is the American Heart Association's flagship journal and the highest-ranked journal in cardiovascular medicine. If you're comparing it with European Heart Journal or JACC, the impact factor confirms what the cardiology community already knows: Circulation sits at the top of the field. The harder question is whether your paper has the clinical consequence and breadth to survive this editorial bar.

Circulation Impact Factor at a Glance

Metric
Value
Impact Factor
38.6
5-Year JIF
35.9
Quartile
Q1
Category Rank
1/98
Percentile
99th
Total Cites
177,978

Among Cardiac & Cardiovascular Systems journals, Circulation ranks in the top 1% by impact factor (JCR 2024). This ranking is based on our analysis of 20,449 journals in the Clarivate JCR 2024 database.

Is the Circulation impact factor going up or down?

Year
Impact Factor
2017
~18.9
2018
~23.1
2019
~23.6
2020
29.7
2021
39.9
2022
37.8
2023
37.8
2024
38.6

Circulation's JIF has been remarkably stable in the 37 to 40 range since 2021. The jump from 29.7 in 2020 to 39.9 in 2021 reflects the wave of heavily cited COVID-cardiovascular papers that boosted many cardiology journals. Unlike some journals that have declined from their pandemic peaks, Circulation has held its elevated position, which suggests the citation gains were structural rather than temporary.

The five-year JIF (35.9) sitting slightly below the two-year (38.6) is normal for a journal whose papers generate strong initial citations. Clinical cardiology papers tend to be cited most heavily in the first two years, particularly large trials and guideline-adjacent studies. That early-citation pattern is a feature of the field, not a weakness of the journal.

What 38.6 Actually Tells You

An impact factor of 38.6 places Circulation in the top echelon of all medical journals, not just cardiology. For context, NEJM is at 78.5 and The Lancet at 88.5, but those are general medicine journals that draw citations from every specialty. Within cardiovascular medicine specifically, 38.6 is the highest JIF in the category.

The number tells you that Circulation papers are cited intensively and quickly. What it doesn't tell you is whether your specific paper will match that average. Citation distribution within the journal is skewed: large trials and guideline papers generate hundreds or thousands of citations, while smaller studies may accumulate far fewer. The JIF is a journal-level average, not a prediction for any individual paper.

How Circulation Compares

Journal
IF (2024)
5-Year JIF
What it rewards
Circulation
38.6
38.6
High-consequence cardiovascular research (AHA)
European Heart Journal
35.6
35.6
Large-scale cardiology with European guideline reach
JACC
22.3
24.2
Clinically visible cardiology with strong society reach
Circulation Research
16.2
16.2
Basic and translational cardiovascular science
Cardiovascular Research
13.3
13.3
Mechanistic cardiovascular biology

The Circulation vs. European Heart Journal comparison is the one most cardiology authors care about. The two journals are close on JIF (38.6 vs. 35.6) and compete for many of the same submissions. The practical difference is geographic reach and society alignment: Circulation is the AHA journal, European Heart Journal is the ESC journal. Papers that align with AHA guidelines or address questions in the American cardiovascular context often fit Circulation better, while European registry studies and ESC-adjacent research often land more naturally at EHJ.

JACC (22.3) is the third member of the top cardiology tier. The JIF gap between Circulation and JACC is meaningful, but JACC has a strong clinical identity and reach within interventional cardiology, heart failure, and imaging subspecialties through its family of journals.

What Pre-Submission Reviews Reveal About Circulation Submissions

In our pre-submission review work on manuscripts targeting Circulation, three patterns account for most of the desk rejections we see.

Clinically sound studies that stop short of a practice consequence. Circulation's documented desk rejection rate is approximately 70-75%. The editorial team makes most of those decisions quickly, median immediate rejection time is 9 days according to SciRev author reports. What triggers fast rejection is not poor science but the absence of a clear practice consequence for a broad cardiovascular audience. The explicit editorial standard, confirmed across AHA editorial communications and documented in submission guidance, is whether the work changes how a broad cardiovascular audience interprets practice, prognosis, or disease biology. We see well-designed observational cohort studies, imaging studies, and mechanistic translational papers that are technically rigorous but whose conclusion is primarily relevant to one subspecialty audience. Papers reporting on a novel biomarker in a specific cardiac phenotype, or validating an imaging protocol in a single-center population, frequently hit this wall regardless of methodological quality. The distinction Circulation editors draw is between papers that add evidence for what is already being discussed and papers that move the cardiovascular conversation forward in a way the whole field will feel.

Statistical design and reporting issues that survive initial review but fail independent statistical evaluation. Circulation's editorial office is documented to send papers for independent statistical review when warranted. The specific red flags they evaluate include: post-hoc analyses submitted as if they were pre-specified primary endpoints, uncorrected multiple testing across a large number of secondary endpoints, and missing confidence intervals on the primary findings. We see papers where the main claim relies on a subgroup analysis that was identified after the data were available, with the statistical presentation written as if the hypothesis drove the design. Circulation reviewers are calibrated to the methodological standards of major clinical trial reporting (CONSORT, STROBE), and papers that cannot distinguish clearly between primary and exploratory analyses put themselves in a difficult position regardless of the headline result. The practical fix is making the pre-specification explicit and presenting post-hoc findings as clearly labeled exploratory rather than weaving them into the primary narrative.

Subspecialty-dominant papers submitted to the flagship instead of the AHA family journal that actually fits. The AHA Circulation family has titles for arrhythmia and electrophysiology (Circ: Arrhythmia and Electrophysiology, IF 9.8), heart failure (Circ: Heart Failure, IF 8.4), interventional cardiology (Circ: Cardiovascular Interventions, IF 7.4), and imaging (Circ: Cardiovascular Imaging, IF 7.0). Circulation's scope is explicitly broad cardiovascular, not broad by the standards of a subspecialty community but broad by the standards of the cardiologist who needs to read across all of these domains. We see EP papers, heart failure device studies, and advanced imaging protocols submitted to Circulation because the authors read the impact factor as a quality signal rather than a scope signal. Circulation's documented editorial response to these papers is usually a suggestion to submit to the more appropriate subspecialty title within the AHA portfolio. Understanding this family structure before choosing where to submit is the simplest available intervention for avoiding a predictable desk rejection.

What Editors Are Really Screening For

Circulation editors screen for papers that change cardiovascular practice, interpretation, or understanding at a level the broad cardiology community will care about. Technical quality alone doesn't clear the bar. The question is always: does this change what cardiologists do or think?

What gets past the desk:

  • Large clinical trials with clear practice implications
  • Studies that address questions cardiologists are actively debating
  • Translational work with a convincing bridge to clinical relevance
  • Epidemiological findings that reshape cardiovascular risk understanding
  • Guideline-adjacent evidence from well-powered designs

What gets desk-rejected:

  • Strong physiology or imaging papers where the consequence feels too narrow
  • Small single-center studies without broader generalizability
  • Basic science without clear translational framing
  • Incremental findings that don't move a clinical conversation forward

Should You Submit to Circulation?

Submit if:

  • The paper matters to a broad cardiovascular audience, not just one subspecialty
  • There's clear consequence for clinical interpretation, prognosis, or management
  • The study design is strong enough to survive the most demanding peer review
  • The manuscript can stand in the top cardiology conversation globally

Think twice if:

  • The work is strong but mostly relevant within one subspecialty (consider a Circulation subspecialty journal instead)
  • The clinical consequence is still indirect or speculative
  • A top subspecialty journal (Circulation Research, JACC subspecialty journals) would actually serve the audience better
  • European Heart Journal is the more natural home based on registry data, population, or guideline alignment

For high-stakes cardiology submissions, running a Circulation clinical significance check can clarify whether the framing and clinical consequence are strong enough for this bar.

The Circulation Journal Family

Circulation sits at the top of an AHA journal family that includes several subspecialty titles:

Journal
IF (2024)
Focus
Circulation
38.6
Broad cardiovascular research
Circulation Research
16.2
Basic and translational CV science
Circ: Arrhythmia and Electrophysiology
9.8
Arrhythmia and EP
Circ: Heart Failure
8.4
Heart failure
Circ: Cardiovascular Interventions
7.4
Interventional cardiology
Circ: Cardiovascular Imaging
7.0
Cardiovascular imaging

This family structure is useful strategically. If a manuscript is strong but too narrow for the flagship, Circulation editors sometimes suggest transfer to a subspecialty title. Understanding this cascade can help authors plan realistic submission strategies rather than treating a Circulation desk rejection as the end of the road.

What the Impact Factor Does Not Tell You

  • Whether the paper is broad enough for Circulation's audience
  • Whether the editorial triage will see it as too subspecialized
  • How the paper compares against what Circulation has been publishing recently
  • Whether European Heart Journal or JACC is actually the better fit
  • How long the review process will take (varies widely)

The JIF is a citation average. It doesn't predict editorial decisions, and it doesn't tell you anything about the specific editorial culture or recent publication patterns at the journal.

This page is most useful when you read it alongside the next-step pages in the same journal cluster:

  • Circulation submission process
  • Circulation review time
  • Circulation under review

Bottom Line

Circulation has an impact factor of 38.6, with a five-year JIF of 35.9 and rank 1/98 in Cardiac & Cardiovascular Systems. It's the top-ranked cardiology journal and the AHA's flagship. Use that to set expectations for the editorial bar, then focus on the real question: does your paper change cardiovascular practice or interpretation at a level this audience will care about immediately?

Frequently asked questions

38.6 (JCR 2024), Q1, rank 1/98 in Cardiac and Cardiovascular Systems. The five-year JIF is 35.9. Circulation is the American Heart Association flagship journal and the top-ranked cardiology journal.

Both are extremely selective (approximately 5-8% acceptance). Circulation (IF 38.6) and JACC (IF 19.9) serve overlapping but different audiences. Circulation leans toward population health and translational science. JACC leans toward interventional cardiology.

Circulation (IF 38.6) and European Heart Journal (IF 35.6) are the two dominant cardiology journals. Circulation is the AHA flagship, EHJ is the ESC flagship. For European trials and ESC-guideline work, EHJ may be better.

Approximately 5-8%. Most submissions are desk-rejected. Papers need broad cardiovascular relevance, not just strong subspecialty science.

Papers that change how a broad cardiovascular audience interprets practice, prognosis, or disease biology. Subspecialty-facing work will likely be desk-rejected despite good science.

References

Sources

  1. Clarivate Journal Citation Reports (latest JCR release used for this page)
  2. Circulation journal information and author guidance
  3. American Heart Association journals homepage

Reference library

Use the core publishing datasets alongside this guide

This article answers one part of the publishing decision. The reference library covers the recurring questions that usually come next: whether the package is ready, what drives desk rejection, how journals compare, and what the submission requirements look like across journals.

Open the reference library

Before you upload

Want the full picture on Circulation?

Scope, selectivity, what editors want, common rejection reasons, and submission context, all in one place.

These pages attract evaluation intent more than upload-ready intent.

Anthropic Privacy Partner. Zero-retention manuscript processing.

Internal navigation

Where to go next

Open Circulation Guide